Sarepta Therapeutics Stock Forecast for 2023 - 2025 - 2030
Updated on 04/23/2024
Sarepta Therapeutics Stock Forecast and Price Target
Given the average yearlong price target of $165.50 provided by six prominent analysts over the past few months, there is a potential upside of approximately 41.31% from the last closing price in April, 2024 for Sarepta Therapeutics's stock if it is reached. This estimation is based on a high estimate of $224.00 and a low estimate of $128.00. If you're looking to buy Sarepta Therapeutics stock, you may also want to check out its rivals.
41.31% Upside
Sarepta Therapeutics Fair Value Forecast for 2023 - 2025 - 2030
Sarepta Therapeutics's Price has seen impressive growth In the last four years, rising from $0.00 to $0.00 – a growth of 100.00%. In the next year, analysts believe that Fair Value will reach $126.13 – an increase of 100.00%. For the next seven years, the forecast is for Fair Value to grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| PFE Stock Forecast | Pfizer | Outperform |
2
|
$26.32 | Buy/Sell | $32.87 | 15.88% |
| SAN Stock Forecast | Sanofi | Outperform |
16
|
88.85€ | Buy/Sell | 102.80€ | 21.55% |
| 4568 Stock Forecast | Daiichi Sankyo Company | Buy |
4
|
¥4.66k | Buy/Sell | ¥5.24k | 24.38% |
| 4502 Stock Forecast | Takeda Pharmaceutical Company | Outperform |
5
|
¥4.12k | Buy/Sell | ¥4.74k | 10.38% |
| MRNA Stock Forecast | Moderna | Outperform |
16
|
$107.89 | Buy/Sell | $135.42 | 15.30% |
Sarepta Therapeutics Revenue Forecast for 2023 - 2025 - 2030
Sarepta Therapeutics's Revenue has seen impressive growth In the last two years, rising from $540.10M to $933.01M – a growth of 72.75%. In the next year, analysts believe that Revenue will reach $2.12B – an increase of 126.80%. For the next seven years, the forecast is for Revenue to grow by 336.22%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BIIB Stock Forecast | Biogen | Outperform |
10
|
$193.18 | Buy/Sell | $299.62 | 51.15% |
| BAX Stock Forecast | Baxter International Inc | Outperform |
17
|
$41.02 | Buy/Sell | $44.86 | 9.70% |
| ALNY Stock Forecast | Alnylam Pharmaceuticals Inc | Outperform |
7
|
$146.07 | Buy/Sell | $245.24 | 47.19% |
.jpg)
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BMRN Stock Forecast | BioMarin Pharmaceutical | Outperform |
10
|
$92.06 | Buy/Sell | $111.56 | 18.94% |
| IONS Stock Forecast | Ionis Pharmaceuticals | Outperform |
9
|
$41.84 | Buy/Sell | $55.60 | 43.88% |
| DYN Stock Forecast | Dyne Therapeutics | Buy |
5
|
$25.44 | Buy/Sell | $28.13 | 41.51% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 4516 Stock Forecast | Nippon Shinyaku | Outperform |
18
|
¥4.30k | Buy/Sell | ¥8.34k | 51.34% |
| DCPH Stock Forecast | Deciphera Pharmaceuticals | Outperform |
6
|
$14.67 | Buy/Sell | $23.40 | 67.01% |
| WVE Stock Forecast | Wave Life Sciences | Outperform |
6
|
$5.08 | Buy/Sell | $9.21 | 165.75% |
Sarepta Therapeutics EBITDA Forecast for 2023 - 2025 - 2030
In the last two years, Sarepta Therapeutics's EBITDA has seen a drop from $-537.15M to $-488.39M – a 9.08% decrease. According to 5 major analysts, Sarepta Therapeutics's EBITDA will fall by 164.24% in the next year, reaching $313.75M. Professionals believe that By 2030, Sarepta Therapeutics's EBITDA will fall to $1.64B– a 436.12% decrease from its current value.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| STOK Stock Forecast | Stoke Therapeutics | Buy |
4
|
$11.25 | Buy/Sell | $19.33 | 86.67% |
| ABUS Stock Forecast | Arbutus Biopharma | Outperform |
9
|
$2.75 | Buy/Sell | $6.34 | 97.45% |
| FULC Stock Forecast | Fulcrum Therapeutics | Outperform |
9
|
$7.44 | Buy/Sell | $10.21 | 94.89% |
Sarepta Therapeutics EBIT Forecast for 2023 - 2025 - 2030
In the last two years, Sarepta Therapeutics's EBIT has gone down from $-564.06M to $-530.20M – a 6.00% drop. In the next year, 11 analysts estimate that Sarepta Therapeutics's EBIT will decrease by 158.01%, reaching $307.59M. According to professional forecasts, in 2030, Sarepta Therapeutics's EBIT will decrease by 441.39%, reaching $1.81B.
Sarepta Therapeutics EPS Price Prediction Forecast for 2023 - 2025 - 2030
Sarepta Therapeutics's EPS has seen impressive growth In the last four years, rising from $-5.83 to $0.00 – a growth of 100.00%. In the next year, analysts believe that EPS will reach $2.63 – an increase of 100.00%. For the next seven years, the forecast is for EPS to grow by 100.00%.
.jpg)